🔗 Share this article

The recently developed medications for gonorrhoea in decades are being viewed as a "huge turning point" in the fight against superbug strains of the pathogen, according to health experts.

A Worldwide Challenge

Cases of gonorrhoea are on the rise globally, with estimates suggesting in excess of 82 million infections per year. Notably increased rates are reported in the African continent and countries within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. Within England, cases have hit a all-time high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an important and timely development in the face of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted therapeutic options presently on offer.”

Medical experts are deeply concerned about the rise in antibiotic-resistant strains. The global health body has classified it as a "critical concern". A tracking program found that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Therapies Gain Authorization

Zoliflodacin, alternatively called a brand name, was cleared by the US FDA in mid-December for combating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Experts believe that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, was also approved in concurrent days. This treatment, which is also used to treat UTIs, was proven in research to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin stemmed from a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This authorization represents a huge turning point in the treatment of superbug gonorrhoea, which until now has been outpacing antibiotic development.”

Clinical Trial Results and Worldwide Availability

Based on data detailed in a major medical journal, zoliflodacin successfully treated the vast majority of genital gonorrhoea infections. This puts it on an equal footing with the typical regimen, which uses two antibiotics. The study included over 900 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the ability to license and sell the drug in numerous developing nations.

Doctors treating patients have shared positive views. The availability of a one-pill regimen like this is hailed as a "game-changer" for managing the epidemic. This is deemed crucial to lessen the impact of the illness for individuals and to prevent the spread of untreatable gonorrhoea worldwide.